 Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous in vitro testing has corroborated the antiviral potential of WP1122. 